PURPOSE: Left atrial catheter ablation for patients with atrial fibrillation (AF) requires periprocedural anticoagulation to minimize thromboembolic complications. High rates of major bleeding complications using dabigatran etexilate for periprocedural anticoagulation have been reported, raising concerns regarding its safety during left atrial catheter ablation. We sought to evaluate the safety and efficacy of a dabigatran use strategy versus warfarin, at a single high-volume AF ablation center. METHODS: We performed a retrospective analysis on consecutive patients undergoing left atrial ablation at Vanderbilt Medical Center from January 2011 through August 2012 with a minimum follow-up of 3 months. Patient cohorts were divided into two groups, those utilizing dabigatran etexilate pre- and post-ablation and those undergoing ablation on dose-adjusted warfarin, with or without low-molecular-weight heparin bridging. Dabigatran was held 24-30 h pre-procedure and restarted 4-6 h after hemostasis was achieved. We evaluated all thromboembolic and bleeding complications at 3 months post-ablation. RESULTS: A total of 254 patients underwent left atrial catheter ablation for atrial fibrillation or left atrial flutter. Periprocedural anticoagulation utilized dabigatran in 122 patients and warfarin in 135 patients. Three late thromboembolic complications occurred in the dabigatran group (2.5 %), compared with one (0.7 %) in the warfarin group (p = 0.28). The dabigatran group had similar minor bleeding (2.5 vs. 7.4 %, p = 0.07), major bleeding (1.6 vs. 0.7 %, p = 0.51), and composite of bleeding and thromboembolic complications (6.6 vs. 8.9 %, p = 0.49) when compared to warfarin. There were no acute thromboembolic complications in either group (<24 h post-ablation). CONCLUSIONS: In patients undergoing left atrial catheter ablation for AF or left atrial flutter, use of periprocedural dabigatran etexilate provides a safe and effective anticoagulation strategy compared to warfarin. A prospective randomized study is warranted.
PURPOSE: Left atrial catheter ablation for patients with atrial fibrillation (AF) requires periprocedural anticoagulation to minimize thromboembolic complications. High rates of major bleeding complications using dabigatran etexilate for periprocedural anticoagulation have been reported, raising concerns regarding its safety during left atrial catheter ablation. We sought to evaluate the safety and efficacy of a dabigatran use strategy versus warfarin, at a single high-volume AF ablation center. METHODS: We performed a retrospective analysis on consecutive patients undergoing left atrial ablation at Vanderbilt Medical Center from January 2011 through August 2012 with a minimum follow-up of 3 months. Patient cohorts were divided into two groups, those utilizing dabigatran etexilate pre- and post-ablation and those undergoing ablation on dose-adjusted warfarin, with or without low-molecular-weight heparin bridging. Dabigatran was held 24-30 h pre-procedure and restarted 4-6 h after hemostasis was achieved. We evaluated all thromboembolic and bleeding complications at 3 months post-ablation. RESULTS: A total of 254 patients underwent left atrial catheter ablation for atrial fibrillation or left atrial flutter. Periprocedural anticoagulation utilized dabigatran in 122 patients and warfarin in 135 patients. Three late thromboembolic complications occurred in the dabigatran group (2.5 %), compared with one (0.7 %) in the warfarin group (p = 0.28). The dabigatran group had similar minor bleeding (2.5 vs. 7.4 %, p = 0.07), major bleeding (1.6 vs. 0.7 %, p = 0.51), and composite of bleeding and thromboembolic complications (6.6 vs. 8.9 %, p = 0.49) when compared to warfarin. There were no acute thromboembolic complications in either group (<24 h post-ablation). CONCLUSIONS: In patients undergoing left atrial catheter ablation for AF or left atrial flutter, use of periprocedural dabigatran etexilate provides a safe and effective anticoagulation strategy compared to warfarin. A prospective randomized study is warranted.
Authors: L Samuel Wann; Anne B Curtis; Kenneth A Ellenbogen; N A Mark Estes; Michael D Ezekowitz; Warren M Jackman; Craig T January; James E Lowe; Richard L Page; David J Slotwiner; William G Stevenson; Cynthia M Tracy Journal: J Am Coll Cardiol Date: 2011-02-14 Impact factor: 24.094
Authors: Joachim Stangier; Bengt I Eriksson; Ola E Dahl; Lennart Ahnfelt; Gerhard Nehmiz; Hildegard Stähle; Karin Rathgen; Robbyna Svärd Journal: J Clin Pharmacol Date: 2005-05 Impact factor: 3.126
Authors: Oussama M Wazni; Salwa Beheiry; Tamer Fahmy; Conor Barrett; Steven Hao; Dimpi Patel; Luigi Di Biase; David O Martin; Mohamed Kanj; Mauricio Arruda; Jennifer Cummings; Robert Schweikert; Walid Saliba; Andrea Natale Journal: Circulation Date: 2007-11-12 Impact factor: 29.690
Authors: Ayman A Hussein; David O Martin; Walid Saliba; Deven Patel; Saima Karim; Omar Batal; Mustafa Banna; Michelle Williams-Andrews; Minerva Sherman; Mohamed Kanj; Mandeep Bhargava; Thomas Dresing; Thomas Callahan; Patrick Tchou; Luigi Di Biase; Salwa Beheiry; Bruce Lindsay; Andrea Natale; Oussama Wazni Journal: Heart Rhythm Date: 2009-07-10 Impact factor: 6.343
Authors: Daniel Scherr; Kavita Sharma; Darshan Dalal; David Spragg; Karuna Chilukuri; Alan Cheng; Jun Dong; Charles A Henrikson; Saman Nazarian; Ronald D Berger; Hugh Calkins; Joseph E Marine Journal: J Cardiovasc Electrophysiol Date: 2009-12
Authors: Pasquale Santangeli; Luigi Di Biase; Javier E Sanchez; Rodney Horton; Andrea Natale Journal: Cardiol Res Pract Date: 2011-04-26 Impact factor: 1.866
Authors: Martin Martinek; Marianne Gwechenberger; Daniel Scherr; Clemens Steinwender; Markus Stühlinger; Helmut Pürerfellner; Franz Xaver Roithinger; Lukas Fiedler Journal: Wien Klin Wochenschr Date: 2018-01-25 Impact factor: 1.704
Authors: Christopher V DeSimone; Elisa Madhavan; Sébastien Ebrille; Alejandro A Rabinstein; Paul A Friedman; Samuel J Asirvatham Journal: J Atr Fibrillation Date: 2013-12-31
Authors: Christopher V DeSimone; Malini Madhavan; Elisa Ebrille; Alejandro A Rabinstein; Paul A Friedman; Samuel J Asirvatham Journal: Card Electrophysiol Clin Date: 2014-03